EA201791485A1 - Анти-cd47-антитела и их применения - Google Patents
Анти-cd47-антитела и их примененияInfo
- Publication number
- EA201791485A1 EA201791485A1 EA201791485A EA201791485A EA201791485A1 EA 201791485 A1 EA201791485 A1 EA 201791485A1 EA 201791485 A EA201791485 A EA 201791485A EA 201791485 A EA201791485 A EA 201791485A EA 201791485 A1 EA201791485 A1 EA 201791485A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- methods
- applications
- suggested
- involved
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
В изобретении предлагаются композиции, способы и применения, в которые вовлечены антитела, которые специфично связываются с CD47 человека. Также предлагаются применения и способы, такие как терапевтические способы, диагностические способы и способы получения таких антител.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462098291P | 2014-12-30 | 2014-12-30 | |
PCT/US2015/067642 WO2016109415A1 (en) | 2014-12-30 | 2015-12-28 | Anti-cd47 antibodies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201791485A1 true EA201791485A1 (ru) | 2018-02-28 |
EA037654B1 EA037654B1 (ru) | 2021-04-27 |
Family
ID=56284963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201791485A EA037654B1 (ru) | 2014-12-30 | 2015-12-28 | Анти-cd47-антитела и их применения |
Country Status (17)
Country | Link |
---|---|
US (2) | US10870699B2 (ru) |
EP (1) | EP3240569A4 (ru) |
JP (2) | JP6850255B2 (ru) |
KR (1) | KR102489471B1 (ru) |
CN (1) | CN107530421B (ru) |
AU (1) | AU2015374301B2 (ru) |
BR (1) | BR112017014258A2 (ru) |
CA (1) | CA2972604C (ru) |
CL (1) | CL2017001736A1 (ru) |
CO (1) | CO2017007673A2 (ru) |
EA (1) | EA037654B1 (ru) |
EC (1) | ECSP17041865A (ru) |
HK (1) | HK1245154A1 (ru) |
MX (1) | MX2017008819A (ru) |
SG (2) | SG10202007176TA (ru) |
WO (1) | WO2016109415A1 (ru) |
ZA (1) | ZA201704467B (ru) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016109415A1 (en) | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
CA2980840A1 (en) * | 2015-05-04 | 2016-11-10 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
US11427632B2 (en) * | 2016-07-06 | 2022-08-30 | Celgene Corporation | Antibodies with low immunogenicity and uses thereof |
AU2017336867B2 (en) | 2016-09-29 | 2024-03-14 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
MX2019004691A (es) | 2016-10-20 | 2019-12-09 | I Mab Biopharma Us Ltd | Anticuerpos monoclonales cd47 novedosos y sus usos. |
EP3534965A4 (en) | 2016-11-03 | 2020-06-24 | Trillium Therapeutics Inc. | IMPROVEMENTS IN CD47 BLOCKADERAPY THROUGH HDAC INHIBITORS |
US11352425B2 (en) * | 2016-11-08 | 2022-06-07 | Absos, Llc | Anti-CD47 antibodies |
EP3533804A4 (en) | 2016-11-18 | 2020-06-17 | Beijing Hanmi Pharmaceutical Co., Ltd. | BISPECIFIC ANTIBODY TYPE ANTI-PD -1 / ANTI-HER2 NATURAL ANTIBODY HETERODIMERIC FORM AND PREPARATION THEREOF |
WO2018137705A1 (en) | 2017-01-26 | 2018-08-02 | Zai Lab (Shanghai) Co., Ltd. | Cd47 antigen binding unit and uses thereof |
CN110300603B (zh) * | 2017-02-14 | 2023-04-14 | 亘喜生物科技(上海)有限公司 | Cd47-car-t细胞 |
US20200330590A1 (en) | 2017-03-27 | 2020-10-22 | Celgene Corporation | Methods and compositions for reduction of immunogenicity |
NZ758119A (en) | 2017-04-14 | 2024-03-22 | Tallac Therapeutics Inc | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
BR112020001679A2 (pt) * | 2017-08-02 | 2020-07-21 | Phanes Therapeutics, Inc. | anticorpos anti-cd47 e usos dos mesmos |
MX2020001873A (es) * | 2017-08-18 | 2020-10-22 | Ultrahuman Four Ltd | Agentes de union. |
CA3044097A1 (en) * | 2017-11-10 | 2019-05-16 | I-Mab | Fusion proteins containing cd47 antibodies and cytokines |
AU2018375375A1 (en) | 2017-12-01 | 2020-05-28 | Seagen Inc. | CD47 antibodies and uses thereof for treating cancer |
KR20200093639A (ko) * | 2017-12-04 | 2020-08-05 | 북경한미약품 유한공사 | 천연 항체 구조-유사 헤테로다이머 형태의 항 pd-l1/항 cd47 이중특이성 항체 및 이의 제조 |
WO2019144895A1 (en) * | 2018-01-24 | 2019-08-01 | Nanjing Legend Biotech Co., Ltd. | Anti-cd47 antibodies that do not cause significant red blood cell agglutination |
WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
GB201804860D0 (en) * | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
CN110577597B (zh) * | 2018-06-11 | 2021-10-22 | 康诺亚生物医药科技(成都)有限公司 | 一种阻断CD47和SIRPα相互作用的抗体 |
CN112566662A (zh) * | 2018-06-15 | 2021-03-26 | 阿库鲁斯生物科学公司 | 针对cd47的阻断抗体及其使用方法 |
EP3817769A4 (en) * | 2018-07-05 | 2022-03-30 | Trican Biotechnology Co., Ltd | HUMAN ANTI-CD47 ANTIBODIES AND THEIR USES |
CN110872348B (zh) * | 2018-09-03 | 2021-09-03 | 长春金赛药业有限责任公司 | 人源化抗cd47单克隆抗体及其应用 |
BR112021008332A2 (pt) * | 2018-10-31 | 2021-08-03 | I-Mab Biopharma Us Limited | composição farmacêutica, proteína de fusão, anticorpo que se liga ao cd47 humano, e, métodos para tratar uma doença em um sujeito humano, para aumentar a seletividade de ligação de um anticorpo monoclonal ou biespecífico ao cd47 humano e para ligar um anticorpo cd47 ao cd47 humano |
MX2021010531A (es) | 2019-03-06 | 2021-10-01 | Jiangsu Hengrui Medicine Co | Proteina de fusion bifuncional y uso farmaceutico de la misma. |
TW202045550A (zh) | 2019-04-05 | 2020-12-16 | 美商西建公司 | 腫瘤選擇性結合cd47之抗體之工程 |
JP2022535286A (ja) | 2019-06-07 | 2022-08-05 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてcd47に結合する薬物の干渉を低減するための方法及び試薬 |
US11795210B2 (en) | 2019-07-16 | 2023-10-24 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
WO2021078219A1 (en) * | 2019-10-25 | 2021-04-29 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel anti-cd47 antibodies and uses thereof |
CA3153636A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
CA3169523A1 (en) | 2020-02-28 | 2021-09-02 | Jaume Pons | Transglutaminase-mediated conjugation |
EP4168115A1 (en) | 2020-06-22 | 2023-04-26 | The Board of Trustees of the Leland Stanford Junior University | Tsp-1 inhibitors for the treatment of aged, atrophied or dystrophied muscle |
TW202227480A (zh) * | 2020-09-14 | 2022-07-16 | 美商蘇特羅生物製藥公司 | 使用無細胞蛋白質合成系統來大規模生產抗體之方法 |
US20230365681A1 (en) | 2020-10-07 | 2023-11-16 | Celgene Corporation | Bispecific antibody treatment of lymphoid malignant neoplasm conditions |
EP4256336A1 (en) | 2020-12-06 | 2023-10-11 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
EP4050029A4 (en) * | 2020-12-23 | 2023-07-12 | Guangdong Feipeng Pharmaceutical Co., Ltd | ANTIBODIES AGAINST CD47 AND USE THEREOF |
WO2022148412A1 (zh) | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | 特异性结合cd47的抗体及其抗原结合片段 |
US20220305100A1 (en) | 2021-03-12 | 2022-09-29 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
TW202330504A (zh) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | 嗒𠯤—3(2h)—酮衍生物 |
US11919869B2 (en) | 2021-10-29 | 2024-03-05 | Gilead Sciences, Inc. | CD73 compounds |
US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024005423A1 (ko) * | 2022-06-29 | 2024-01-04 | 고려대학교 산학협력단 | 인간 FCγRS 결합력이 제거된 당화 FC 변이체들 |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
US20240010714A1 (en) * | 2022-07-10 | 2024-01-11 | Mbrace Therapeutics, Inc. | Cell-free methods of recombinant antibody production |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AU2161501A (en) | 1999-11-29 | 2001-06-25 | Unilever Plc | Immobilized single domain antigen-binding molecules |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2008115732A2 (en) | 2007-03-20 | 2008-09-25 | Eli Lilly And Company | Anti-sclerostin antibodies |
EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
WO2011004847A1 (ja) * | 2009-07-07 | 2011-01-13 | 一般財団法人化学及血清療法研究所 | 新規ヒト化抗ヒトα9インテグリン抗体 |
SI2477648T1 (sl) | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
JP2014519338A (ja) * | 2011-06-16 | 2014-08-14 | ノバルティス アーゲー | 治療薬として使用される可溶性タンパク質 |
JP6460796B2 (ja) * | 2012-01-17 | 2019-01-30 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 高親和性sirp−アルファ試薬 |
US20140140989A1 (en) | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
SI2812443T1 (sl) | 2012-02-06 | 2019-10-30 | Inhibrx Inc | Protitelesa CD47 in postopki za njihovo uporabo |
KR102276974B1 (ko) * | 2013-02-06 | 2021-07-13 | 인히브릭스, 인크. | 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법 |
SG11201508642WA (en) * | 2013-04-19 | 2015-11-27 | Sutro Biopharma Inc | Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones |
WO2016109415A1 (en) | 2014-12-30 | 2016-07-07 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
NZ740686A (en) | 2015-09-18 | 2021-12-24 | Arch Oncology Inc | Therapeutic cd47 antibodies |
JP2018535692A (ja) | 2015-09-21 | 2018-12-06 | エラスムス ユニバーシティ メディカル センターErasmus University Medical Center | 抗cd47抗体及び使用方法 |
-
2015
- 2015-12-28 WO PCT/US2015/067642 patent/WO2016109415A1/en active Application Filing
- 2015-12-28 JP JP2017535814A patent/JP6850255B2/ja active Active
- 2015-12-28 BR BR112017014258A patent/BR112017014258A2/pt active Search and Examination
- 2015-12-28 SG SG10202007176TA patent/SG10202007176TA/en unknown
- 2015-12-28 CA CA2972604A patent/CA2972604C/en active Active
- 2015-12-28 EP EP15876093.4A patent/EP3240569A4/en active Pending
- 2015-12-28 AU AU2015374301A patent/AU2015374301B2/en active Active
- 2015-12-28 MX MX2017008819A patent/MX2017008819A/es unknown
- 2015-12-28 CN CN201580077136.5A patent/CN107530421B/zh active Active
- 2015-12-28 EA EA201791485A patent/EA037654B1/ru unknown
- 2015-12-28 US US15/541,003 patent/US10870699B2/en active Active
- 2015-12-28 SG SG11201705310TA patent/SG11201705310TA/en unknown
- 2015-12-28 KR KR1020177021330A patent/KR102489471B1/ko active IP Right Grant
-
2017
- 2017-06-29 CL CL2017001736A patent/CL2017001736A1/es unknown
- 2017-06-30 EC ECIEPI201741865A patent/ECSP17041865A/es unknown
- 2017-06-30 ZA ZA2017/04467A patent/ZA201704467B/en unknown
- 2017-07-28 CO CONC2017/0007673A patent/CO2017007673A2/es unknown
-
2018
- 2018-04-17 HK HK18104961.7A patent/HK1245154A1/zh unknown
-
2020
- 2020-10-29 US US16/949,459 patent/US11787860B2/en active Active
- 2020-12-01 JP JP2020199312A patent/JP2021048858A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ECSP17041865A (es) | 2017-08-31 |
KR20170100652A (ko) | 2017-09-04 |
CA2972604C (en) | 2023-07-04 |
HK1245154A1 (zh) | 2018-08-24 |
CO2017007673A2 (es) | 2018-01-05 |
US20170369572A1 (en) | 2017-12-28 |
BR112017014258A2 (pt) | 2018-03-06 |
EP3240569A4 (en) | 2018-05-30 |
CL2017001736A1 (es) | 2018-03-16 |
JP2018506964A (ja) | 2018-03-15 |
CA2972604A1 (en) | 2016-07-07 |
EA037654B1 (ru) | 2021-04-27 |
US10870699B2 (en) | 2020-12-22 |
SG10202007176TA (en) | 2020-08-28 |
WO2016109415A1 (en) | 2016-07-07 |
US11787860B2 (en) | 2023-10-17 |
AU2015374301A1 (en) | 2017-07-20 |
ZA201704467B (en) | 2019-09-25 |
JP6850255B2 (ja) | 2021-03-31 |
CN107530421B (zh) | 2021-07-20 |
SG11201705310TA (en) | 2017-07-28 |
AU2015374301B2 (en) | 2021-02-11 |
JP2021048858A (ja) | 2021-04-01 |
CN107530421A (zh) | 2018-01-02 |
KR102489471B1 (ko) | 2023-01-18 |
US20210054070A1 (en) | 2021-02-25 |
MX2017008819A (es) | 2018-03-14 |
EP3240569A1 (en) | 2017-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
EA202092435A2 (ru) | Моноклональные антитела против bcma | |
EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201791164A1 (ru) | Гетеродимерные антитела, связывающие cd3 и cd38 | |
EA202091540A1 (ru) | Антитела к lilrb2 | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
EA201792414A1 (ru) | Антитела против cd166, активируемые антитела против cd166 и способы их применения | |
EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EA201692394A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
EA201790173A1 (ru) | Антитела, связывающие axl | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
EA201691610A8 (ru) | Анти-jagged1 антитела и способы применения | |
PH12017501077A1 (en) | Compositions and methods for antibodies targeting bmp6 | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
EA201890347A1 (ru) | Антитела и исследования для обнаружения cd37 | |
EA201990978A1 (ru) | Антитела против pd-1 | |
MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. |